Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (A264)

• ClinicalTrials.gov Identifier: NCT04152499
• Recruitment Status: Recruiting
• First Posted: November 5, 2019
• Last Update Posted: July 12, 2022
• Sponsor: Klus Pharma Inc.
• Information provided by (Responsible Party): Klus Pharma Inc.

Study Description

Brief Summary:

A Phase I-II, First-in-Human Study of SKB264 in Patients with Locally Advanced Unresectable/Metastatic Solid Tumors who are refractory to Available Standard Therapies. Patient must have historically documented, incurable, locally advanced or metastatic cancer that are refractory to standard therapies of one of the following types:

1. Triple negative breast cancer
2. Epithelial ovarian cancer
3. Non-small cell lung cancer
4. Gastric adenocarcinoma
5. Small cell lung cancer
6. Urothelial carcinoma

Condition or disease	Intervention/treatment	Phase
Ovarian Epithelial Cancer; Gastric Adenocarcinoma; Breast Cancer; Urothelial Carcinoma; Non-Small Cell Lung Cancer; Small-Cell Lung Cancer	Drug: SKB264	Phase 1; Phase 2

Detailed Description:

This is an open label, Phase I-II, first in human (FIH) study for SKB264 as monotherapy in patients who have locally advanced unresectable or metastatic solid tumor that is refractory to all standard therapies. TROP2 (trophoblast antigen 2) assessments will not be performed prior to enrollment but it will be assessed retrospectively. Confirmation of TROP2 (trophoblast antigen 2) expression by immunohistology or other means is not required, but the Sponsor will request fresh tumor biopsy or tissue specimens from archived materials for determination of TROP2 (trophoblast antigen 2) expression retrospectively. The patient must be, in the judgment of the investigator, an appropriate candidate for experimental therapy whose tumor is refractory to standard therapies. Patients will receive study drug as a single IV infusion at the prescribed dose level at each administration. Cycles will continue until disease progression or unacceptable toxicity. The study is divided into 2 parts (Phase I and Phase II).

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 250 participants
• Allocation: Non-Randomized
• Intervention Model: Sequential Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase I-II, First-in-Human Study of SKB264 in Patients With Locally Advanced Unresectable /Metastatic Solid Tumors Who Are Refractory to Available Standard Therapies
• Actual Study Start Date: February 28, 2020
• Estimated Primary Completion Date: November 2024
• Estimated Study Completion Date: December 2025

Arms and Interventions

Arm	Intervention/treatment
Experimental: Phase I: Dose Escalation; Five dose levels have been selected for evaluation in the Phase I part of the study: 2, 4, 6, 9, and 12 mg/kg of SKB264	Drug: SKB264; SKB264 is an Antibody Drug Conjugate (ADC) targeting TROP2 expressing cancer cells.
Experimental: Phase II: Triple Negative Breast cancer; Histologically documented, incurable, locally advanced or metastatic cancer	Drug: SKB264; SKB264 is an Antibody Drug Conjugate (ADC) targeting TROP2 expressing cancer cells.
Experimental: Phase II: Ovarian Epithelial cancer; Histologically documented, incurable, locally advanced or metastatic cancer	Drug: SKB264; SKB264 is an Antibody Drug Conjugate (ADC) targeting TROP2 expressing cancer cells.
Experimental: Phase II: Non-Small Cell Lung Cancer; Histologically documented, incurable, locally advanced or metastatic cancer	Drug: SKB264; SKB264 is an Antibody Drug Conjugate (ADC) targeting TROP2 expressing cancer cells.
Experimental: Phase II: Gastric Adenocarcinoma; Histologically documented, incurable, locally advanced or metastatic cancer	Drug: SKB264; SKB264 is an Antibody Drug Conjugate (ADC) targeting TROP2 expressing cancer cells.
Experimental: Phase II: Small Cell Lung Cancer; Histologically documented, incurable, locally advanced or metastatic cancer	Drug: SKB264; SKB264 is an Antibody Drug Conjugate (ADC) targeting TROP2 expressing cancer cells.
Experimental: Phase II: Urothelial Carcinoma; Histologically documented, incurable, locally advanced or metastatic cancer	Drug: SKB264; SKB264 is an Antibody Drug Conjugate (ADC) targeting TROP2 expressing cancer cells.

Outcome Measures

Primary Outcome Measures :

1. Phase I: Maximum Tolerated Dose (MTD) and Recommended Doses for Expansion (RDEs) [ Time Frame: Assess up to 12 months ]
   To determine the maximum tolerated dose (MTD) and/or recommended doses for expansion (RDEs). RDEs will not exceed MTD.
2. Phase II: Objective Response Rate (ORR) [ Time Frame: Time Frame: From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months ]
   To evaluate the objective response rate (ORR) [Complete Response (CR) + Partial Response (PR)] of SKB264 when administered intravenously (IV) as monotherapy at the RDEs to patients with metastatic or locally advanced unresectable tumors.

Secondary Outcome Measures :

1. Phase I: Dose Limiting Toxicities (DLTs) [ Time Frame: Day 28 days after first infusion of study drug ]
   To determine the dose limiting toxicities (DLTs) of SKB264 when administered IV twice (on Days 1 and 15) every 2 weeks in 4 weeks (28 days) cycles as monotherapy to patients with metastatic or locally advanced unresectable tumors.
2. Phase I: Overall safety and tolerability profile [ Time Frame: Assessed up to end of study, approximately 12 months ]
   To determine the treatment emergent adverse events by severity and by dose level of SKB264 when administered IV twice (on Days 1 and 15) every 2 weeks in 4 weeks (28 days) cycles as monotherapy to patients with metastatic or locally advanced unresectable tumors.
3. Phase I: Preliminary efficacy based on ORR (Objective Response Rate) [ Time Frame: From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, approximately 12 months ]
   ORR (Objective Response Rate) as determined by the Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1, which will be complete response (CR) + partial response (PR)
4. Phase I: Preliminary efficacy based on DOR(Duration of Response) [ Time Frame: From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, approximately 12 months ]
   To evaluate preliminary efficacy in patients treated with SKB264 as monotherapy based on DOR(Duration of Response).
5. Phase I: Preliminary efficacy based on PFS(Progression-Free Survival) [ Time Frame: From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, approximately 12 months ]
   To evaluate preliminary efficacy in patients treated with SKB264 as monotherapy based on PFS(Progression-Free Survival).
6. Phase I: Preliminary efficacy based on OS(Overall Survival) [ Time Frame: From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, approximately 12 months ]
   To evaluate preliminary efficacy in patients treated with SKB264 as monotherapy based on OS(Overall Survival)
7. Phase I and II: Anti-drug Antibodies (ADA) [ Time Frame: From Cycle 1 to Cycle 6 and End of Treatment(EOT), approximately 12 months ]
   To assess the incidence of anti-drug antibody (ADA) formation to SKB264.
8. Phase I and II: Levels of TROP2 expression in tumor tissue [ Time Frame: Screening and End of Treatment(EOT), approximately 12 months ]
   To assess levels of TROP2 expression in tumor tissue and correlation of those levels with responses and toxicity.
9. Phase I and II: Characterization of PK_Cmax [ Time Frame: From Cycle 1 to Cycle 6 and End of Treatment(EOT), approximately 12 months ]
   To characterize the PK of SKB264-TAB, such as Cmax
10. Phase I and II: Characterization of PK_AUC (Area Under the Curve) [ Time Frame: From Cycle 1 to Cycle 6 and End of Treatment(EOT), approximately 12 months ]
    To characterize the PK of SKB264-TAB, such as AUC (Area Under the Curve)
11. Phase I and II: Characterization of PK_Half life [ Time Frame: From Cycle 1 to Cycle 6 and End of Treatment(EOT), approximately 12 months ]
    To characterize the PK of SKB264-TAB, such as half life
12. Phase II: Recommended Doses for Expansion (RDEs) [ Time Frame: After Day 28 from the first infusion at each dose level in Phase Ⅰ ]
    To obtain additional characterization of the safety of SKB264 at the RDEs.
13. Phase II: Efficacy based on DOR(Duration of Response) [ Time Frame: From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, approximately 12 months. ]
    To evaluate efficacy in patients treated with SKB264 as monotherapy based on DOR(Duration of Response)
14. Phase II: Efficacy based on PFS (Progression-Free Survival) [ Time Frame: From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, approximately 12 months. ]
    To evaluate efficacy in patients treated with SKB264 as monotherapy based on PFS (Progression-Free Survival)
15. Phase II: Efficacy based on OS (Overall Survival) [ Time Frame: From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, approximately 12 months. ]
    To evaluate efficacy in patients treated with SKB264 as monotherapy based on OS (Overall Survival)

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 75 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

Phase I:

1. Patients must be able to provide documented voluntary informed consent.
2. Male or female patient aged 18-75 years.

3. Histologically documented, incurable, locally advanced or metastatic epithelial origin malignant cancer , priority to include but not limited to the following tumor types:

   • Breast cancer
   • Ovarian epithelial cancer
   • Non-small cell lung cancer
   • Gastric adenocarcinoma
   • Small cell lung cancer
   • Urothelial cancers

   Note: Confirmation of TROP2 expression by immunohistology or other means is not required, but the Sponsor will request tissue specimens from fresh or archived materials for determination of TROP2 expression.

4. Measurable disease by CT/MRI during dose escalation.
5. Patients should have an unresectable locally advanced or metastatic solid tumor that is refractory to standard therapies, or have no standard therapies, or standard treatment is not applicable at this stage.
6. Granulocyte count ≥ 1.5×109/L, platelet count ≥ 100×109/L, and hemoglobin ≥ 9 g/dL.
7. International normalized ratio (INR) and activated partial thromboplastin time (aPTT) ≤ 1.5×ULN.
8. Serum bilirubin ≤ 1.5 mg/dL (Patients with known Gilbert disease who have serum bilirubin level ≤ 3 ×ULN may be enrolled)., aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase ≤ 2.5 × upper limit of normal (ULN), with the exception of patients with hepatic metastases (ALT and AST ≤ 5 × ULN) and patients with hepatic and/or bone metastases (alkaline phosphatase ≤ 5 × ULN).
9. Creatinine clearance ≥ 50 mL/min calculated by Cockcroft-Gault, Chronic Kidney Disease Epidemiology Collaboration, or Modification of Diet in Renal Disease formulas. Note that 24 hour urine collection is not required but is allowed.
10. Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1.

11. For female patients of childbearing potential and male patients with partners of childbearing potential, agreement (by patient and/or partner) to use a highly effective form(s) of contraception during study treatment . Female and male patient treated with SKB264 should continue contraception use for 7 months after the last dose. Such methods include combined (estrogen and progestogen containing) hormonal contraception, progestogen-only hormonal contraception associated with inhibition of ovulation together with another additional barrier method always containing a spermicide, intrauterine device (IUD), intrauterine hormonereleasing system (IUS), bilateral tubal occlusion or vasectomized partner (on the understanding that this is the only one partner during the whole study duration), and sexual abstinence.

    • Oral contraception should always be combined with an additional contraceptive method because of a potential interaction with the study drug. The same rules are valid for male patients involved in this clinical trial if they have a partner of childbirth potential. Male patients must always use a condom.
    • Women are excluded from birth control if they had had tubal ligation or a hysterectomy.
12. Patients must have recovered (i.e., improvement to Grade 1 or better) from all acute toxicities from previous therapy, excluding alopecia and vitiligo.
13. Expected survival ≥ 3 months.

Phase II:

1. Patients must be able to provide documented voluntary informed consent.
2. Male or female patient aged 18-75 years.

3. Histologically documented, incurable, locally advanced or metastatic cancer, priority to include but not limited to the following tumor types (the sponsor will add or remove indications based on real-time study results):

   • Triple negative breast cancer
   • Epithelial ovarian cancer
   • Non-small cell lung cancer
   • Gastric adenocarcinoma
   • Small cell lung cancer
   • Urothelial carcinoma

   Note: Confirmation of TROP2 expression by immunohistology or other means is not required, but the Sponsor will request tissue specimens from fresh or archived materials for determination of Trop-2 expression

4. Measurable disease by CT/MRI.
5. Patients should have an unresectable locally advanced or metastatic solid tumor that is refractory to standard therapies, or have no standard therapies, or standard treatment is not applicable at this stage.
6. Granulocyte count ≥ 1.5×109/L, platelet count ≥ 100×109/L, and hemoglobin ≥ 9 g/dL.
7. International normalized ratio (INR) and activated partial thromboplastin time (aPTT) ≤ 1.5×ULN.
8. Serum bilirubin ≤ 1.5 mg/dL (Patients with known Gilbert disease who have serum bilirubin level ≤ 3 ×ULN may be enrolled)., aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase ≤ 2.5 × upper limit of normal (ULN), with the exception of patients with hepatic metastases (ALT and AST ≤ 5 × ULN) and patients with hepatic and/or bone metastases (alkaline phosphatase ≤ 5 × ULN).
9. Creatinine clearance ≥ 50 mL/min calculated by Cockcroft-Gault, Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI), or Modification of Diet in Renal Disease (MDRD) formulas. Note that 24 hour urine collection is not required but is allowed.
10. ECOG Performance Status 0 or 1.

11. For female patients of childbearing potential and male patients with partners of childbearing potential, agreement (by patient and/or partner) to use a highly effective form(s) of contraception during study treatment. Female and male patient treated with SKB264 should continue contraception use for 7 months after the last dose. Such methods include combined (estrogen and progestogen containing) hormonal contraception, progestogen-only hormonal contraception associated with inhibition of ovulation together with another additional barrier method always containing a spermicide, intrauterine device (IUD), intrauterine hormonereleasing system (IUS), bilateral tubal occlusion or vasectomized partner (on the understanding that this is the only one partner during the whole study duration), and sexual abstinence.

    • Oral contraception should always be combined with an additional contraceptive method because of a potential interaction with the study drug. The same rules are valid for male patients involved in this clinical trial if they have a partner of childbirth potential. Male patients must always use a condom.
    • Women are excluded from birth control if they had had tubal ligation or a hysterectomy.
12. Patients must have recovered (i.e., improvement to Grade 1 or better) from all acute toxicities from previous therapy, excluding alopecia and vitiligo.
13. Expected survival ≥ 3 months.

Exclusion Criteria:

Phase I:

1. Severe or uncontrolled cardiac disease requiring treatment, congestive heart failure (New York Heart Association) III or IV, unstable angina pectoris even if medically controlled, history of myocardial infarction during the last 6 months, serious arrhythmias requiring medication (with exception of atrial fibrillation or paroxysmal supraventricular tachycardia).
2. Symptomatic brain metastases or any radiation or surgery for brain metastases within 3 months of first infusion of study drug.
3. Subjects with second primary cancers (except for cured in situ non-melanoma skin cancer and in situ cervical cancer with no relapse in the last 3 years).
4. Require supplemental oxygen for daily activities.
5. Documented Grade ≥ 2 peripheral neuropathy.
6. History of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, corneal disease that prevents/delays corneal healing, macular degeneration.
7. Subjects previously treated with TROP 2 targeted therapies.
8. Any standard cancer therapy (e.g chemotherapy, hormonal therapy, radiotherapy, immunotherapy, biologic therapy treatment, or therapy with traditional Chinese medicines approved for anti-tumor treatment, etc.) within 4 weeks or five half-lives, whichever is shorter, of first infusion of study drug.
9. Any experimental therapy within 4 weeks or five half-lives, whichever is shorter, of first infusion of study drug.
10. Any major surgical procedure within 4 weeks of first infusion of study drug.
11. Diagnosed active liver disease, including viral or other hepatitis, current or history of alcoholism, or cirrhosis.
12. Have known prior positive test results or medical history for human immunodeficiency virus.
13. Uncontrolled hypertension (systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 100 mmHg) or diabetes (HbA1c ≥ 9.0%).
14. Subjects who require use of strong inhibitors or inducers of CYP3A4 at least 14 days prior to and throughout Study. Use of strong inhibitors or inducers of CYP3A4 is not allowed in this study. List of representative examples of strong inhibitors or inducers of CYP3A4 is provided in Appendix III.
15. Pregnancy or lactation.
16. Left ventricular ejection fraction < 45% determined by echocardiogram or multiple gated acquisition scan.
17. Resting QTc > 480 msec at baseline.
18. Ascites requiring paracentesis ≥1 per week.
19. Symptomatic pleural effusion (< 90% oxygen saturation).
20. Subjects with non-infectious interstitial lung diseases (ILD) or medical history of pneumonia requiring steroid treatments; severe pulmonary dysfunction caused by lung diseases.
21. New diagnosed thromboembolic events that requires therapeutic intervention over the last 6 months (patients with stable control of lower limb deep venous thrombosis are allowed).
22. The investigator considers other situations that patients are not appropriate to participate in this trial.

Phase II:

1. Any patient who was treated in the Phase I part of this study.
2. Severe or uncontrolled cardiac disease requiring treatment, congestive heart failure (New York Heart Association) III or IV, unstable angina pectoris even if medically controlled, history of myocardial infarction during the last 6 months, serious arrhythmias requiring medication (with exception of atrial fibrillation or paroxysmal supraventricular tachycardia).
3. Symptomatic brain metastases or any radiation or surgery for brain metastases within 3 months of first infusion of study drug.
4. Subjects with second primary cancers (except for cured in situ non-melanoma skin cancer and in situ cervical cancer with no relapse in the last 3 years).
5. Require supplemental oxygen for daily activities.
6. Documented Grade ≥ 2 peripheral neuropathy.
7. History of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, corneal disease that prevents/delays corneal healing, macular degeneration.
8. Subjects previously treated with TROP 2 targeted therapies.
9. Any standard cancer therapy (e.g chemotherapy, hormonal therapy, radiotherapy, immunotherapy, or biologic therapy treatment, or therapy with traditional Chinese medicines approved for anti-tumor treatment, etc.) within 4 weeks or 5 half-lives, whichever is shorter, of first infusion of study drug.
10. Any experimental therapy within 4 weeks or 5 half-lives, whichever is shorter, of first infusion of study drug.
11. Any major surgical procedure within 4 weeks of first infusion of study drug.
12. Diagnosed active liver disease, including viral or other hepatitis, current or history of alcoholism, or cirrhosis.
13. Have known prior positive test results or medical history for human immunodeficiency virus.
14. Uncontrolled hypertension (systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 100 mmHg) or diabetes (HbA1c ≥ 9.0%).
15. Subjects who require use of strong inhibitors or inducers of CYP3A4 at least 14 days prior to and throughout Study. Use of strong inhibitors or inducers of CYP3A4 is not allowed in this Study. List of representative examples strong inhibitors or inducers of CYP3A4 is provided in Appendix III.
16. Pregnancy or lactation.
17. Left ventricular ejection fraction < 45% determined by echocardiogram or multiple gated acquisition scan.
18. Resting QTc > 480 msec at baseline.
19. Ascites requiring paracentesis ≥1 per week.
20. Symptomatic pleural effusion (< 90% oxygen saturation).
21. Subjects with non-infectious interstitial lung diseases (ILD) or medical history of pneumonia requiring steroid treatments; severe pulmonary dysfunction caused by lung diseases.
22. New diagnosed thromboembolic events that requires therapeutic intervention over the last 6 months (patients with stable control of lower limb deep venous thrombosis are allowed).
23. The investigator considers other situations that patients are not appropriate to participate in this trial.

Contacts and Locations

Contacts

Contact: Study Manager; 2678887498; jean.mastrangelo@kluspharma.com

Locations

United States, California

University of California Los Angeles; Recruiting

Los Angeles, California, United States, 90404

Contact: Zev Wainberg

United States, District of Columbia

Georgetown University; Withdrawn

Washington, District of Columbia, United States, 20057

United States, Florida

Florida Cancer Specialists and Research Institute; Recruiting

Sarasota, Florida, United States, 34232

Contact: Judy Wang

United States, Massachusetts

Beth Israel Deaconess Medical Center; Completed

Boston, Massachusetts, United States, 02215

United States, Michigan

START MidWest; Recruiting

Grand Rapids, Michigan, United States, 49546

Contact: Manish Sharma

United States, Oklahoma

The University of Oklahoma Health Sciences Center; Active, not recruiting

Oklahoma City, Oklahoma, United States, 73104

United States, Oregon

Providence Cancer Institute, Franz Clinic; Recruiting

Portland, Oregon, United States, 97213

Contact: Rachel Sanborn

United States, Texas

Mary Crowley Cancer Research; Active, not recruiting

Dallas, Texas, United States, 75230

MD Anderson Cancer Center; Recruiting

Houston, Texas, United States, 77030

Contact: Jordie Rodon

United States, Virginia

Virginia Cancer Specialists; Recruiting

Fairfax, Virginia, United States, 22031

Contact: Alexander Spira

China, Anhui

The Second Hospital of Anhui Medical University; Recruiting

Hefei, Anhui, China

Contact: Zhendong Chen

China, Chongqing

Chongqing University Cancer Hosptital; Recruiting

Chongqing, Chongqing, China

Contact: Yongsheng Li

China, Fujian

The First Affiliated Hospital Of Xiamen University; Recruiting

Xiamen, Fujian, China

Contact: Yanjun Mi

China, Guangdong

Sun Yat-sen University Cancer Center; Recruiting

Guangzhou, Guangdong, China

Contact: Li Zhang, PhD

China, Guangzhou

Sun Yat-sen University Cancer Center; Recruiting

Guangzhou, Guangzhou, China

Contact: Li Zhang

China, Hangzhou

Zhejiang Cancer Hospital; Recruiting

Gongshu, Hangzhou, China

Contact: Yun Fan

China, Henan

The First Affiliated Hospital of Zhengzhou University; Recruiting

Zhengzhou, Henan, China

Contact: Xingya Li

China, Hunan

Hunan Cancer Hospital; Recruiting

Changsha, Hunan, China

Contact: Yongzhong Luo

Hunan Cancer Hospital; Recruiting

Changsha, Hunan, China

Contact: Wei Wang

China, Shandong

Shandong Cancer Hospital; Recruiting

Jinan, Shandong, China

Contact: Bo Liu

China, Sichuan

West China Hospital of Sichuan University; Recruiting

Chengdu, Sichuan, China

Contact: Shuang Zhang

China, Wuhan

Hubei Cancer Hospital; Recruiting

Hongshan, Wuhan, China

Contact: Huiting Xu

China, Zhejiang

SIR RUN RUN SHAW Hospital, ZHEJIANG University School of Medicine; Recruiting

Hangzhou, Zhejiang, China

Contact: Xian Wang

The First Affiliated Hospital, Zhejiang University School of Medicine; Recruiting

Hangzhou, Zhejiang, China

Contact: Nong Xu

Zhejiang Cancer Hospital; Recruiting

Hangzhou, Zhejiang, China

Contact: Yun Fan

China

Beijing Cancer Hospital; Recruiting

Beijing, China

Contact: Yunong Gao

Chinese PLA General Hospital (301 Hospital); Recruiting

Beijing, China

Contact: Weihong Zhao

Jilin Cancer Hospital; Recruiting

Changchun, China

Contact: Ying Cheng

Hunan Cancer Hospital; Recruiting

Changsha, China

Contact: Quchang Ouyang

The Second Hospital of Dalian Medical University; Recruiting

Dalian, China

Contact: Kui Jiang

Sun Yat-Sen Memorial Hospital , Sun Yat-sen University; Recruiting

Guangzhou, China

Contact: Ying Wang

Harbin Medical University Cancer Hospital; Recruiting

Harbin, China

Contact: Ge Lou

Hunan Cancer Hospital; Recruiting

Hunan, China

Contact: Keqiang Zhang

Jiangsu Province Hospital; Recruiting

Nanjing, China

Contact: Yongmei Yin

Shandong Cancer Hospital; Recruiting

Shandong, China

Contact: Lihua Song

Shanghai East Hospital; Recruiting

Shanghai, China

Contact: Jin Li, MD

Principal Investigator: Jin Li, MD

Zhongshan Hospital, Fudan University; Recruiting

Shanghai, China

Contact: Tianshu Liu

Liaoning Cancer Hospital; Recruiting

Shenyang, China

Contact: Danbo Wang

The First Hospital of China Medical University; Recruiting

Shenyang, China

Contact: Yunpeng Liu

The Fourth Hospital of Hebei Medical University; Recruiting

Shijiazhuang, China

Contact: Cuizhi Geng

Tianjin Cancer Hospital; Recruiting

Tianjin, China

Contact: Zhongsheng Tong

Weifang People's Hospital; Recruiting

Weifang, China

Contact: Guohua Yu

Hubei Cancer Hospital; Recruiting

Wuhan, China

Contact: Xinhong Wu

The First Affiliated Hospital of Xi'an Jiaotong University; Recruiting

Xi'an, China

Contact: Ruifang An

Xuzhou Central Hospital; Recruiting

Xuzhou, China

Contact: Xiang Wang

Henan Cancer Hospital; Recruiting

Zhengzhou, China

Contact: Min Yan

Sponsors and Collaborators

Klus Pharma Inc.

Investigators

• Study Chair: Jordi Rodon Ahnert, MD, PhD; M.D. Anderson Cancer Center

More Information

• Responsible Party: Klus Pharma Inc.
• ClinicalTrials.gov Identifier: NCT04152499
• Other Study ID Numbers: KL264-01
• First Posted: November 5, 2019
• Last Update Posted: July 12, 2022
• Last Verified: July 2022

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Klus Pharma Inc.:

TROP2, ADC

Additional relevant MeSH terms:

Lung Neoplasms; Small Cell Lung Carcinoma; Carcinoma, Ovarian Epithelial; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases; Carcinoma, Bronchogenic; Bronchial Neoplasms; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Ovarian Neoplasms; Endocrine Gland Neoplasms; Ovarian Diseases; Adnexal Diseases; Genital Neoplasms, Female; Urogenital Neoplasms; Endocrine System Diseases; Gonadal Disorders